1.7.1.13	C190A	complete loss of activity	724767	
1.7.1.13	D197N	complete loss of activity	724767	
1.7.1.13	E230Q	about 4% of wild-type activity for natural substrate 2-amino-5-cyanopyrrolo[2,3-d]pyrimidin-4-one	724767	
1.7.1.13	F228W	about 8% of wild-type activity for natural substrate 2-amino-5-cyanopyrrolo[2,3-d]pyrimidin-4-one	724767	
1.7.1.13	H229A	about 15% of wild-type activity for natural substrate 2-amino-5-cyanopyrrolo[2,3-d]pyrimidin-4-one	724767	
1.7.1.13	Q89A	poor activity	724767	
1.7.1.13	Q89L	poor activity	724767	
1.7.1.13	S90A	about 10% of wild-type activity for natural substrate 2-amino-5-cyanopyrrolo[2,3-d]pyrimidin-4-one	724767	
1.7.1.13	C99A	mutant does not compromise enzyme activity. Contrary to wild-type, peroxide-induced inactivation is irreversible	-, 742061	
1.7.1.13	C99S	mutant does not compromise enzyme activity. Contrary to wild-type, peroxide-induced inactivation is irreversible	-, 742061	
1.7.1.13	C190A	mutation in catalytic residue, no evidence of covalent binding of substrate preQ0. Mutant displays proton uptake	742900	
1.7.1.13	C190A	the mutation annihilates preQ0 covalent binding and largely disrupts the nitrile-to-amine reductase activity	764418	
1.7.1.13	C190S	the mutation annihilates preQ0 covalent binding and largely disrupts the nitrile-to-amine reductase activity	764418	
1.7.1.13	D197A	the variant does not take up protons in conjunction with preQ0 binding	764418	
1.7.1.13	D197H	the variant recovers proton uptake to a level almost analogous to that seen with the wildtype enzyme	764418	
1.7.1.13	H229A	the variant readily forms the thioimidate adduct and is 24fold less active for preQ0 reduction than wild type enzyme	764418	
1.7.1.13	E89A	the variant performs primarily (more than 90%) a two-electron reduction of 7-cyano-7-deazaguanine (preQ0), releasing hydrolyzed imine (7-formyl-7-deazaguanine) as the product	765048	
1.7.1.13	E89L	the variant performs primarily (more than 90%) a two-electron reduction of 7-cyano-7-deazaguanine (preQ0), releasing hydrolyzed imine (7-formyl-7-deazaguanine) as the product	765048	
1.7.1.13	F228A	the variant performs primarily (more than 90%) a two-electron reduction of 7-cyano-7-deazaguanine (preQ0), releasing hydrolyzed imine (7-formyl-7-deazaguanine) as the product	765048	
1.7.1.13	I192A	the 7-cyano-7-deazaguanine (preQ0) reduction by the mutant gives 7-aminomethyl-7-deazaguanine (preQ1) and 7-formyl-7-deazaguanine at a 1:1 ratio	765048	
1.7.1.13	L191A	the 7-cyano-7-deazaguanine (preQ0) reduction by the mutant gives 7-aminomethyl-7-deazaguanine (preQ1) and 7-formyl-7-deazaguanine at a 4:1 ratio	765048